ice1991
2021-11-23
.
Novartis May Have Buyer(s) For Its Sandoz Unit - Report
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
2
8
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":875528274,"tweetId":"875528274","gmtCreate":1637671730524,"gmtModify":1637671730524,"author":{"id":3558581401862827,"idStr":"3558581401862827","authorId":3558581401862827,"authorIdStr":"3558581401862827","name":"ice1991","avatar":"https://static.tigerbbs.com/ff847f0a64ccaa96b7b1f4ae7cb40ef7","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":3,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>.</p></body></html>","htmlText":"<html><head></head><body><p>.</p></body></html>","text":".","highlighted":1,"essential":1,"paper":1,"likeSize":8,"commentSize":2,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/875528274","repostId":1136165340,"repostType":4,"repost":{"id":"1136165340","kind":"news","pubTimestamp":1637671478,"share":"https://www.laohu8.com/m/news/1136165340?lang=&edition=full","pubTime":"2021-11-23 20:44","market":"us","language":"en","title":"Novartis May Have Buyer(s) For Its Sandoz Unit - Report","url":"https://stock-news.laohu8.com/highlight/detail?id=1136165340","media":"Benzinga","summary":"According to a German newspaper, Swedish-based investment group EQT and the Struengmann family of Ge","content":"<ul>\n <li>According to a German newspaper, Swedish-based investment group EQT and the Struengmann family of Germany are considering a joint move to purchase the <b>Novartis AG's</b> generics outfit, Sandoz, for $21.6 billion.</li>\n</ul>\n<ul>\n <li>The price would make it the largest pharma deal of the year.</li>\n <li>EQT and the Struengmanns, who provided the investment power behind <b>BioNTech SE</b>, have attracted interest from other private equity investors to join the group, the outlet reported.</li>\n <li>Reuters points out that the Struengmann twins have done business with Novartis in the past, selling a generics maker, Hexal, to the company in 2005.</li>\n <li>Similar divestitures have been made by other pharmaceutical giants designed to focus on the business of developing drugs.</li>\n <li><b>Merck & Co Inc</b> has created <b>Organon & Co</b>. <b>Pfizer Inc</b> merged its generics maker, Upjohn, with <b>Mylan</b>, creating <b>Viatris Inc</b>.</li>\n <li>Most recently,<b>Johnson & Johnson</b> revealed it was establishing a new publicly-traded company to handle its consumer health business.</li>\n <li>Novartis was nearing the sale of a portion of its generics business to Aurobindo of India for $1 billion before the deal fell through after an antitrust review setback with the U.S. Federal Trade Commission.</li>\n <li><b>Price Action:</b> NVS shares are up 0.97% at $82.11 during the premarket session on the last check Tuesday.</li>\n</ul>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novartis May Have Buyer(s) For Its Sandoz Unit - Report</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovartis May Have Buyer(s) For Its Sandoz Unit - Report\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-23 20:44 GMT+8 <a href=https://www.benzinga.com/m-a/21/11/24244480/novartis-may-have-buyer-s-for-its-sandoz-unit-report><strong>Benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>According to a German newspaper, Swedish-based investment group EQT and the Struengmann family of Germany are considering a joint move to purchase the Novartis AG's generics outfit, Sandoz, for $21.6 ...</p>\n\n<a href=\"https://www.benzinga.com/m-a/21/11/24244480/novartis-may-have-buyer-s-for-its-sandoz-unit-report\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVS":"诺华"},"source_url":"https://www.benzinga.com/m-a/21/11/24244480/novartis-may-have-buyer-s-for-its-sandoz-unit-report","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1136165340","content_text":"According to a German newspaper, Swedish-based investment group EQT and the Struengmann family of Germany are considering a joint move to purchase the Novartis AG's generics outfit, Sandoz, for $21.6 billion.\n\n\nThe price would make it the largest pharma deal of the year.\nEQT and the Struengmanns, who provided the investment power behind BioNTech SE, have attracted interest from other private equity investors to join the group, the outlet reported.\nReuters points out that the Struengmann twins have done business with Novartis in the past, selling a generics maker, Hexal, to the company in 2005.\nSimilar divestitures have been made by other pharmaceutical giants designed to focus on the business of developing drugs.\nMerck & Co Inc has created Organon & Co. Pfizer Inc merged its generics maker, Upjohn, with Mylan, creating Viatris Inc.\nMost recently,Johnson & Johnson revealed it was establishing a new publicly-traded company to handle its consumer health business.\nNovartis was nearing the sale of a portion of its generics business to Aurobindo of India for $1 billion before the deal fell through after an antitrust review setback with the U.S. Federal Trade Commission.\nPrice Action: NVS shares are up 0.97% at $82.11 during the premarket session on the last check Tuesday.","news_type":1},"isVote":1,"tweetType":1,"viewCount":823,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":1,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/875528274"}
精彩评论